ANI Pharmaceuticals vs Harrow
ANIP and HROW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIP and HROW compare
ANI Pharmaceuticals is the larger company, worth 1.5 times as much as Harrow ($1.6B against $1.1B).
ANI Pharmaceuticals grew revenue faster over the last twelve months (30.9% versus 21.1% for Harrow).
ANI Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 11.1% compared with −13.5% at Harrow.
ANI Pharmaceuticals scores higher on the StockData Score (14 against 6 for Harrow), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIP | HROW |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $1.1B |
| Share price | $70.89 | $29.09 |
| Change, 1 year | −16.2% | −23.2% |
| Change, 5 years | 73.9% | 183% |
| Beta (5Y) | 0.63 | 2.11 |
| Employees | 970 | 373 |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 15.1× | – |
| P/S | 1.7× (better) | 4.0× |
| P/B | 2.7× (better) | 71.7× |
| EV/EBITDA | 6.6× | – |
| P/FCF | 9.4× (better) | 217× |
| FCF yield | 10.6% (better) | 0.46% |
| Fair value | $134.15 | – |
| Margin of safety | 47.2% | – |
| Growth | ||
| Revenue growth (TTM) | 30.9% (better) | 21.1% |
| Revenue growth, 5Y average | 33.5% | 41.0% (better) |
| Profitability | ||
| Gross margin | 60.4% | 73.3% (better) |
| Operating margin | 15.4% (better) | −1.00% |
| Net margin | 11.1% (better) | −13.5% |
| FCF margin | 17.7% (better) | 1.8% |
| Return on equity | 21.0% (better) | −115% |
| Return on invested capital | 21.3% (better) | −1.7% |
| Financial health | ||
| Debt / equity | 0.50 (better) | 19.24 |
| Net debt / EBITDA | −0.25 | – |
| Interest coverage | 4.8× (better) | −0.1× |
| Current ratio | 2.91 (better) | 2.24 |
| Altman Z-score | 2.54 (better) | 1.96 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Payout ratio | 0.32% | – |
| Buyback yield | 1.4% | – |
| Shareholder yield | 1.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 100% | 57.4% |
| Held by insiders | 12.3% | 14.2% |
| Insider net buying, 12 months | −$13.6M | −$9.2M (better) |
| Short interest, % of float | 17.8% | 22.1% |
Go deeper
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
- HROW stock overview
- HROW income statement
- HROW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.